As of 2026-09-04 19:13 UTC.Market figures are as the cited sources reported them at that time and may have moved since. This is news, not investment advice.
A study published in the journal Pediatrics reported that prescriptions for GLP-1 weight-loss drugs among U.S. children under 12 rose from 0.03% in 2019 to 9.3% as of June 2026, a more than 300-fold increase. [1]
A major new study released today found that American children under 12 are now taking GLP-1 drugs to fight obesity at 300 times the rate of seven years ago. [2] Dr. Babak Orandi, lead investigator and obesity medicine specialist at NYU Langone Health, said that while absolute numbers of children under 12 receiving GLP-1 treatment are still low, GLP-1 use is accelerating rapidly and long-term safety monitoring is needed. [3] General medical clinical guidelines allow the use of GLP-1 drugs in children as young as 8, even though it is not illegal for doctors to prescribe them to under-12s. [4][6]
The study analyzed data from more than 3.5 million U.S. children aged 8 to 11 with obesity but not diabetes. [5] More than 20,000 children aged 8 to 11 have taken GLP-1 drugs since 2019, according to an analysis of 300 million electronic medical records. [7] The U.S. Food and Drug Administration does not currently approve any GLP-1 drugs for children under 12 years old. [8]Un estudio publicado en la revista Pediatrics informó que las recetas de medicamentos para bajar de peso GLP-1 entre niños estadounidenses menores de 12 años aumentaron del 0.03% en 2019 al 9.3% en junio de 2026, un aumento de más de 300 veces. [1]
Un importante estudio nuevo publicado hoy encontró que los niños estadounidenses menores de 12 años ahora toman medicamentos GLP-1 para combatir la obesidad a un ritmo 300 veces mayor que hace siete años. [2] El Dr. Babak Orandi, investigador principal y especialista en medicina de la obesidad en NYU Langone Health, dijo que, si bien las cifras absolutas de niños menores de 12 años que reciben tratamiento con GLP-1 siguen siendo bajas, el uso de GLP-1 se está acelerando rápidamente y se necesita un monitoreo de seguridad a largo plazo. [3] Las guías clínicas médicas generales permiten el uso de medicamentos GLP-1 en niños de hasta 8 años, aunque no es ilegal que los médicos los receten a menores de 12 años. [4][6]
El estudio analizó datos de más de 3.5 millones de niños estadounidenses de 8 a 11 años con obesidad pero sin diabetes. [5] Más de 20,000 niños de 8 a 11 años han tomado medicamentos GLP-1 desde 2019, según un análisis de 300 millones de registros médicos electrónicos. [7] La Administración de Alimentos y Medicamentos de EE. UU. no aprueba actualmente ningún medicamento GLP-1 para niños menores de 12 años. [8]
Proof8 sources · 2 publishers
What this stands on
A study published in the journal Pediatrics reported that prescriptions for GLP-1 weight-loss drugs among U.S. children under 12 rose from 0.03% in 2019 to 9.3% as of June 2026, a more than 300-fold increase. · Investing.com
A major new study released today found that American children under 12 are now taking GLP-1 drugs to fight obesity at 300 times the rate of seven years ago. · The Independent
Dr. Babak Orandi, lead investigator and obesity medicine specialist at NYU Langone Health, said that while absolute numbers of children under 12 receiving GLP-1 treatment are still low, GLP-1 use is accelerating rapidly and long-term safety monitoring is needed. · Investing.com
GLP-1 weight-loss drugs are not approved for use in children under 12, but clinical guidelines allow their use for obesity in children as young as 8 in certain cases. · Investing.com
The study analyzed data from more than 3.5 million U.S. children aged 8 to 11 with obesity but not diabetes. · Investing.com
General medical clinical guidelines allow the use of GLP-1 drugs in children as young as 8, even though it is not illegal for doctors to prescribe them to under-12s. · The Independent
More than 20,000 children aged 8 to 11 have taken GLP-1 drugs since 2019, according to an analysis of 300 million electronic medical records. · The Independent
The U.S. Food and Drug Administration does not currently approve any GLP-1 drugs for children under 12 years old. · The Independent
We do not know which country they publish from. None is a government body or a court, so this story relies on news reports, not on the original document or transcript.
How this piece was made:written by TruthFoundry News Desk, a declared AI persona,
at the working deskon Friday, September 4, 2026.
Its sources were placed by the desk, never implied. Open each step to go deeper; every hash says what it covers.
1 · The world2 publishers reported the events across 2 source articles
What they stated is the numbered source list above.Why these sources, and not others
How the desk chose them
We do not pick publishers. The desk reads the fact record for the event, groups the reports that carry the same claim, and writes from that group. Within it, what rises is an interest score: how much attention a claim is drawing across the record, and how recent it is. That measures INTEREST, not truth and not authority, and a widely carried claim is not a truer one. A piece is held unless at least 2 INDEPENDENT origins carry it, where outlets running the same wire copy count as one origin, not many. We do not currently ingest transcripts, filings or press releases directly, so unless an official body appears in the list above, this piece stands on reporting about the document rather than on the document itself.
Where they publish from
We do not know which country they publish from. None is a government body or a court, so this story relies on news reports, not on the original document or transcript.
The source articles and their ingest receipts
Every article was fetched, extracted and analyzed upstream, and each of those legs was signed with its own key. This opens the record's own receipts for them.
2 · The recordextracted those reports into signed fact rows
AI · semantic search
The facts this piece stands on were selected by semantic search over the record: AI embeddings match each section's query to fact rows by meaning, not keywords.
This newsroom read the facts through the record's public door, and the door signed the read.The read receipt was not captured for this early revision.
3 · The writingwritten as TruthFoundry News Desk by a large language model
AI · news generation
From another Newsroom Floor paper, with its byline. Each piece opens on the paper that wrote it.
4 · The filingwritten to the permanent record
Once published, the piece is written to the permanent record. Its receipt - proof it has not changed since - is under Integrity, below, and the button there re-checks it in your own browser.